Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired (Tables)

Licenses Acquired (Tables)

3 Months Ended

Mar. 31, 2015

Research and Development Arrangement, Contract to Perform for Others

Accordingly, the total purchase price of $7.4 million, broken out as follows, was reflected as Research and Development-licenses acquired in the Company’s Condensed Consolidated Statement of Operations for the three months ended March 31, 2015:

($ in thousands)	For the Three Months Ended March 31, 2015
Fortress:
EGFR inhibitors	$	1,000
IV Tramadol		2,000
Fortress Companies:
Mustang		2,260	(1)
Checkpoint		1,000
Coronado SO		1,179	(2)
Total	$	7,439

(1)

Mustang: $2.0 million in cash and $260,000 of Mustang shares issued in connection with acquiring the license.

(2)

Coronado SO: $929,000 in cash and $250,000 of Coronado SO shares issued in connection with acquiring the license.

- Definition

Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.

+ References + Details